Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer: early-phase trial registry
275 of 749 indexed Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4 of 28,963 conditions by registered trial count.
749 US clinical trials · 275 currently recruiting · #4 of 28,963 conditions by registered trial count
Prostate Cancer: 749 US clinical trials tracked, 275 recruiting.
Prostate Cancer is the subject of 749 registered US clinical trials on ClinicalTrials.gov, 275 of them currently open to new participants. 75 are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 53 of these trials.
Open enrollment, early-phase tilt
Prostate Cancer has 749 registered US clinical trials, 275 of them open to new participants right now, about 37% of the total.
- 275
- recruiting participants now
- 37%
- of trials open to enrollment
- 75
- in Phase 3-4 (later-stage)
- 53
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #4 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer recruits in line with its size-band peers.
275 of 749 indexed trials (36.7%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 53 of 749 trials (7.1%). 283 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Cancer enrolment sits around 82 participants.
Median target enrolment is 82 among the 736 trials that report a genuine target (sentinel values excluded). 389 of those (52.9%) plan for fewer than 100 participants.
-
Prostate Cancer research is mostly interventional.
628 interventional and 121 observational studies make up this index (83.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
749 total, page 2 of 15
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Amgen
NCT04221542
Connect2Care: Prostate Cancer Education and Screenings for African American Men
University of Oklahoma
NCT07055165
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
VA Office of Research and Development
NCT04787744
Active Surveillance for Cancer of the Prostate (ASCaP)
Jonsson Comprehensive Cancer Center
NCT00949819
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT04751435
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Novartis Pharmaceuticals
NCT06780670
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Curium US
NCT06235151
Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
University of Oklahoma
NCT07014618
The Effect of IBD Flares on Serum PSA
Northwestern University
NCT03558048
Prostate Cancer Genetic Risk Evaluation and Screening Study
Massachusetts General Hospital
NCT05129605
Stereotactic Magnetic Resonance Guided Radiation Therapy
Dana-Farber Cancer Institute
NCT04115254
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
NYU Langone Health
NCT06397703
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Clarity Pharmaceuticals
NCT06056830
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
National Cancer Institute (NCI)
NCT05588128
PRISM: Patient Experiences With PET Imaging in Prostate Cancer
Yale University
NCT06523777
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
University of British Columbia
NCT04812366
Precise Oncology Interventions in Nutrition and Training (OnPoint)
University of Miami
NCT06534918
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
Brigham and Women's Hospital
NCT07427043
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
National Cancer Institute (NCI)
NCT01834001
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals
NCT04585750
Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation
NYU Langone Health
NCT07203482
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT00588185
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
University of Texas Southwestern Medical Center
NCT03769766
PSMA-PET to Guide Prostatectomy
Five Eleven Pharma
NCT05381103
RCT of NLP-Based Feedback for Improving SDM in Men With Localized Prostate Cancer
Cedars-Sinai Medical Center
NCT06856694
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Case Comprehensive Cancer Center
NCT05610852
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Janux Therapeutics
NCT05519449
DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer
Lauren Hamel
NCT04766190
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeiGene
NCT06257264
Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
M.D. Anderson Cancer Center
NCT05043012
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Pathos AI
NCT06785636
Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer
University of California, San Francisco
NCT05396872
Using a mHealth App to Improve Quality-of-Life Outcomes in Black Prostate Cancer Survivors
University of Oklahoma
NCT06651359
Preop Laxatives in Robotic Urologic Surgery
Chad R. Tracy
NCT05805436
Outcomes of Focal Ablation for Prostate Cancer
University of Texas Southwestern Medical Center
NCT05478694
Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)
University of California, San Diego
NCT05882253
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
Memorial Sloan Kettering Cancer Center
NCT02706561
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
Northwestern University
NCT05424783
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT06545942
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
Clarity Pharmaceuticals
NCT06970847
Designing Visual Tools to Enhance Cancer Surgeon Decision-making
UNC Lineberger Comprehensive Cancer Center
NCT06965192
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06014255
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Astellas Pharma Global Development
NCT07005154
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
NCT05787587
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT05169970
Improving Health Literacy in African-American Prostate Cancer Patients
Emory University
NCT03322891
Micro-UltraSound In Cancer - Active Surveillance
University of Alberta
NCT05558241
Virtual Reality Headset and/or Aromatherapy for Patients Undergoing a Transperineal Prostate Biopsy
University of Pittsburgh
NCT06296147
Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
Massachusetts General Hospital
NCT01961713
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Phrontline Biopharma
NCT07181473
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 188 |
| Phase 3 | 62 |
| Phase 4 | 13 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Prostate Cancer right now
275 recruiting of 749 indexed (37% open).
Phase mix: 75 late (III/IV) vs 344 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (53 trials), 9 others listed. 50 shown below, recruiting first. #4 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Prostate Cancer?
PlainTrial tracks 749 US clinical trials for Prostate Cancer, of which 275 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Prostate Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.